Announcement • Jun 25
Alps Group Inc Launches Patient-Derived Organoid Program To Advance Personalized Cancer Care In Southeast Asia Alps Group Inc. announced its expansion into patient-derived organoid (PDO) technology through a Research and Collaboration Agreement with Dr. Kong Wai Mun, Executive Director of Axiocell Biotech and a biomedical scientist with more than 17 years of experience in translational research and preclinical model development. Under the agreement, Alps is launching an internal PDO program targeting personalized cancer treatment and preclinical drug screening, a fast-growing field in precision oncology. According to Future Market Insights, the global human organoids market was valued at approximately USD 91.8 million in 2026 and is projected to reach USD 349.5 million by 2036, growing at a CAGR of 14.3%. The global personalized cancer treatment market was valued at approximately USD 222.54 billion in 2026 and is projected to reach USD 332.37 billion by 2030, growing at a CAGR of 10.5%. Alps aims to develop Malaysia’s first clinically validated PDO platform with a defined regulatory pathway that includes obtaining MREC ethics approval and Medical Device Authority (MDA) regulatory registration to support clinical deployment and commercialization. PDO technology involves growing three-dimensional “mini-tumors” from a patient’s own cancer tissue, allowing clinicians and researchers to evaluate how individual tumors may respond to different therapies. This approach is designed to improve treatment selection, accelerate drug development, and reduce reliance on animal testing. Alps plans to establish a national PDO biobank to support preclinical drug screening and licensing services for pharmaceutical and CRO partners, with a long-term goal of positioning Malaysia as a regional hub for PDO-based translational research. The program has identified initial clinical interest across six major oncology centers in Malaysia. According to GLOBOCAN 2022, Malaysia records approximately 51,650 new cancer cases per year. The Malaysia National Cancer Registry Report further notes that 64.8% of cases are diagnosed at advanced stages. Announcement • May 20
Alps Group Inc Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency On May 15, 2026, Alps Group Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that based on the closing bid price of the ordinary shares of the Company for the last 30 consecutive business days, the Company is currently not in compliance with the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5450(a)(1), which requires the Company to maintain a minimum bid price of $1.00 per share. The notification has no immediate effect on the listing or trading of the Company's ordinary shares on Nasdaq, and it does not affect the Company's current business operations or financial condition. Nasdaq has provided the Company with a compliance period of 180 calendar days, or until November 11, 2026, in which to regain compliance with Nasdaq continued listing requirement. In the event that the Company does not regain compliance in the compliance period, the Company may be eligible for an additional 180 calendar days, should the Company meet the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement, and is able to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company's securities will be subject to delisting. The Company is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq's continued listing requirement. Although the Company will use all reasonable efforts to achieve compliance, there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement. Announcement • Apr 18
Alps Group Inc Appoints Hee H. Lee as Independent Director, Member of Audit and Compensation Committee, Effective April 17, 2026 Alps Group Inc. announced the appointment of Mr. Hee H. Lee to its Board of Directors, effective April 17, 2026. The Company's Board will increase from five to six directors in connection with this appointment. Mr. Lee is considered independent under applicable Nasdaq rules and is expected to serve as a member of the Audit Committee and the Compensation Committee. Mr. Lee has over 35 years of experience in public accounting and advisory services, including his tenure as a Partner at Ernst & Young LLP within its Global Financial Services Organization. During his career, Mr. Lee advised boards of directors and senior management of financial institutions on financial reporting, corporate governance, structured transactions, and capital markets matters. At Ernst & Young, Mr. Lee established and led the Americas Financial Accounting Advisory Services practice within the financial services sector. His experience spans asset management, banking, insurance, private equity, and fintech/digital assets. He has advised on derivatives, securitization, structured financing, initial public offerings, and mergers and acquisitions, and served for more than 20 years as an advisor to the International Swaps and Derivatives Association, contributing to the development and interpretation of industry standards affecting global capital markets. Mr. Lee is a Certified Public Accountant licensed in the State of New York and a member of the American Institute of Certified Public Accountants. He holds a Master of Accountancy and Financial Information Systems from Cleveland State University and a Bachelor of Business Administration from the University of Louisiana at Lafayette. He has also completed executive education programs in board and leadership development at Harvard University and the Kellogg School of Management. 
